Literature DB >> 19011997

A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.

Hitomi Imachi1, Koji Murao, Shouji Ohtsuka, Mako Fujiwara, Tomie Muraoka, Hitoshi Hosokawa, Toshihiko Ishida.   

Abstract

Dunnigan-type familial partial lipodystrophy (FPLD) is a rare monogenic adipose tissue disorder in which the affected subjects have increased predisposition to insulin resistance and related metabolic complications, such as glucose intolerance, diabetes, dyslipidemia, and hepatic steatosis. Our patient was a 35-year-old female who had been receiving insulin injection therapy for diabetes mellitus and was transferred to our hospital. She was diagnosed with FPLD on the basis of the following symptoms: increase in subcutaneous fat in the face, neck, and upper trunk; loss of subcutaneous fat in the lower limbs and the gluteal region. We found a heterozygous CGG to CAG transition in codon 482 of exon 8 in the gene encoding lamin A/C (LMNA), which leads to an arginine to glutamine substitution (R482Q). At the time of admission, her serum creatinine level was 8.4 mg/dl, and her blood urea nitrogen (BUN) level was 81 mg/dl. Her serum creatinine level was elevated and hemodialysis was performed twice every week. However, she died of cerebral hemorrhage 9 months after hemodialysis. Although it is uncommon for patients with FPLD to exhibit renal dysfunction and require hemodialysis, this case suggests the need for careful analysis of renal function in a patient with FPLD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19011997     DOI: 10.1007/s12020-008-9127-1

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  25 in total

1.  Nuclear lamin A/C R482Q mutation in canadian kindreds with Dunnigan-type familial partial lipodystrophy.

Authors:  H Cao; R A Hegele
Journal:  Hum Mol Genet       Date:  2000-01-01       Impact factor: 6.150

2.  LMNA, encoding lamin A/C, is mutated in partial lipodystrophy.

Authors:  S Shackleton; D J Lloyd; S N Jackson; R Evans; M F Niermeijer; B M Singh; H Schmidt; G Brabant; S Kumar; P N Durrington; S Gregory; S O'Rahilly; R C Trembath
Journal:  Nat Genet       Date:  2000-02       Impact factor: 38.330

3.  Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy.

Authors:  M Raffaele Di Barletta; E Ricci; G Galluzzi; P Tonali; M Mora; L Morandi; A Romorini; T Voit; K H Orstavik; L Merlini; C Trevisan; V Biancalana; I Housmanowa-Petrusewicz; S Bione; R Ricotti; K Schwartz; G Bonne; D Toniolo
Journal:  Am J Hum Genet       Date:  2000-03-16       Impact factor: 11.025

4.  Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety).

Authors:  A Garg
Journal:  J Clin Endocrinol Metab       Date:  2000-05       Impact factor: 5.958

5.  Premature atherosclerosis associated with monogenic insulin resistance.

Authors:  R A Hegele
Journal:  Circulation       Date:  2001-05-08       Impact factor: 29.690

6.  Post-mortem findings in familial partial lipodystrophy, Dunnigan variety.

Authors:  W A Haque; F Vuitch; A Garg
Journal:  Diabet Med       Date:  2002-12       Impact factor: 4.359

7.  Familial partial lipodystrophy: complications of obesity in the non-obese?

Authors:  D C Robbins; E S Horton; O Tulp; E A Sims
Journal:  Metabolism       Date:  1982-05       Impact factor: 8.694

Review 8.  Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome.

Authors:  Robert A Hegele
Journal:  Trends Endocrinol Metab       Date:  2003-10       Impact factor: 12.015

Review 9.  Spectrum of renal diseases associated with extreme forms of insulin resistance.

Authors:  Carla Musso; Edward Javor; Elaine Cochran; James E Balow; Phillip Gorden
Journal:  Clin J Am Soc Nephrol       Date:  2006-04-26       Impact factor: 8.237

10.  Mesangiocapillary glomerulonephritis type 2 associated with familial partial lipodystrophy (Dunnigan-Kobberling syndrome).

Authors:  Katharine R Owen; Mollie Donohoe; Sian Ellard; Tom J Clarke; Anthony J Nicholls; Andrew T Hattersley; Coralie Bingham
Journal:  Nephron Clin Pract       Date:  2004
View more
  5 in total

1.  Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.

Authors:  Baris Akinci; Sadiye Mehtat Unlu; Ali Celik; Ilgin Yildirim Simsir; Sait Sen; Banu Nur; Fatma Ela Keskin; Basak Ozgen Saydam; Nilufer Kutbay Ozdemir; Banu Sarer Yurekli; Bekir Ugur Ergur; Melda Sonmez; Tahir Atik; Atakan Arslan; Tevfik Demir; Canan Altay; Ulku Aybuke Tunc; Tugba Arkan; Ramazan Gen; Erdal Eren; Gulcin Akinci; Aslihan Arasli Yilmaz; Habib Bilen; Samim Ozen; Aygul Celtik; Senay Savas Erdeve; Semra Cetinkaya; Huseyin Onay; Sulen Sarioglu; Elif Arioglu Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2018-05-17       Impact factor: 3.478

2.  LMNA gene mutation search in Polish patients: new features of the heterozygous Arg482Gln mutation phenotype.

Authors:  Tomasz Klupa; Magdalena Szopa; Jan Skupien; Katarzyna Wojtyczek; Katarzyna Cyganek; Irina Kowalska; Maciej T Malecki
Journal:  Endocrine       Date:  2009-10-27       Impact factor: 3.633

3.  Computational Exploration for Lead Compounds That Can Reverse the Nuclear Morphology in Progeria.

Authors:  Shailima Rampogu; Ayoung Baek; Minky Son; Amir Zeb; Chanin Park; Raj Kumar; Gihwan Lee; Donghwan Kim; Yeonuk Choi; Yeongrae Cho; Yohan Park; Seok Ju Park; Keun Woo Lee
Journal:  Biomed Res Int       Date:  2017-10-26       Impact factor: 3.411

Review 4.  Mechanisms of vascular calcification in CKD-evidence for premature ageing?

Authors:  Catherine M Shanahan
Journal:  Nat Rev Nephrol       Date:  2013-09-10       Impact factor: 28.314

5.  Familial partial lipodystrophy and proteinuric renal disease due to a missense c.1045C > T LMNA mutation.

Authors:  Athanasios Fountas; Zoe Giotaki; Evangelia Dounousi; George Liapis; Alexandra Bargiota; Agathocles Tsatsoulis; Stelios Tigas
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-06-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.